Long-term survival benefits of intrathecal autologous bone marrow-derived mesenchymal stem cells (Neuronata-R®: lenzumestrocel) treatment in ALS: Propensity-score-matched control, surveillance study

ObjectiveNeuronata-R® (lenzumestrocel) is an autologous bone marrow-derived mesenchymal stem cell (BM-MSC) product, which was conditionally approved by the Korean Ministry of Food and Drug Safety (KMFDS, Republic of Korea) in 2013 for the treatment of amyotrophic lateral sclerosis (ALS). In the pres...

全面介紹

書目詳細資料

發表在:	Frontiers in Aging Neuroscience
Main Authors:	Jae-Yong Nam, Sehwan Chun, Tae Yong Lee, Yunjeong Seo, Kwijoo Kim, Jinseok Park, Wonjae Sung, Ki-Wook Oh, Sanggon Lee, Jin-Sung Park, Juyeon Oh, Kyung Cheon Chung, Hyonggin An, Hyeon Sik Chu, Bugyeong Son, Seung Hyun Kim
格式:	Article
語言:	英语
出版:	Frontiers Media S.A. 2023-04-01
主題:	lenzumestrocel amyotrophic lateral sclerosis stem cell therapy survival analysis mesenchymal stem cell
在線閱讀:	https://www.frontiersin.org/articles/10.3389/fnagi.2023.1148444/full